Welcome to Our Medtech Talk Podcast Channel
Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.
As a trained neurosurgeon, Dr. Chris Mansi is familiar with the challenges patients face in accessing lifesaving treatments. After earning an MBA from Stanford and enrolling in their Biodesign Medical Innovation track, he learned to develop multifaceted and technology-based solutions to improve healthcare workflows.
In this episode, host Geoff Pardo speaks with Mansi about Viz.ai, a revolutionary application that increases patient access to life-saving treatments in over 1,200 hospitals. Every minute an ischemic stroke patient waits for treatment equates to approximately 2 million neurons lost and a week of disability. Viz.ai abbreviates the sometimes five-hour-long process of securing a specialist to merely minutes, changing the course of patients’ lives. Mansi also discusses how to address naivety in entrepreneurship, the value of an interdisciplinary mindset in improving patient outcomes, and the importance of creating a value-based company with mission-driven employees.
Dr. Chris Mansi is a Cambridge/Queen Square-trained neurosurgeon and the CEO and co-founder of Viz.ai. At Stanford Business School, he joined forces with machine learning post-doc Dr. David Golan to found Viz.ai with the goal of using artificial intelligence to make healthcare work faster and smarter, put patients first, and improve access to lifesaving therapies. As a result, Viz.ai was the first FDA-cleared AI computer-aided triage and the first CMS NTAP for AI. Chris cares about healthcare access, building and supporting great teams, transformative technologies, and improving provider experience to effect and scale better patient outcomes.